JP6788586B2 - Hnlを用いる診断方法 - Google Patents
Hnlを用いる診断方法 Download PDFInfo
- Publication number
- JP6788586B2 JP6788586B2 JP2017526552A JP2017526552A JP6788586B2 JP 6788586 B2 JP6788586 B2 JP 6788586B2 JP 2017526552 A JP2017526552 A JP 2017526552A JP 2017526552 A JP2017526552 A JP 2017526552A JP 6788586 B2 JP6788586 B2 JP 6788586B2
- Authority
- JP
- Japan
- Prior art keywords
- hnl
- antibody
- protein
- binding
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002405 diagnostic procedure Methods 0.000 title description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 208
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 171
- 229920001184 polypeptide Polymers 0.000 claims description 153
- 150000001413 amino acids Chemical class 0.000 claims description 135
- 238000009739 binding Methods 0.000 claims description 113
- 230000027455 binding Effects 0.000 claims description 112
- 239000011230 binding agent Substances 0.000 claims description 73
- 210000000440 neutrophil Anatomy 0.000 claims description 56
- 239000000203 mixture Substances 0.000 claims description 43
- 238000004458 analytical method Methods 0.000 claims description 34
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 210000002966 serum Anatomy 0.000 claims description 17
- 210000002381 plasma Anatomy 0.000 claims description 15
- 239000000872 buffer Substances 0.000 claims description 8
- 210000001185 bone marrow Anatomy 0.000 claims description 7
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 7
- 102000019298 Lipocalin Human genes 0.000 claims description 5
- 108050006654 Lipocalin Proteins 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- 206010036790 Productive cough Diseases 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 286
- 238000000034 method Methods 0.000 description 177
- 102000004169 proteins and genes Human genes 0.000 description 167
- 235000018102 proteins Nutrition 0.000 description 161
- 235000001014 amino acid Nutrition 0.000 description 136
- 239000002773 nucleotide Substances 0.000 description 112
- 125000003729 nucleotide group Chemical group 0.000 description 112
- 239000000523 sample Substances 0.000 description 100
- 208000035143 Bacterial infection Diseases 0.000 description 90
- 208000022362 bacterial infectious disease Diseases 0.000 description 90
- 210000004027 cell Anatomy 0.000 description 90
- 239000000427 antigen Substances 0.000 description 73
- 102000036639 antigens Human genes 0.000 description 73
- 108091007433 antigens Proteins 0.000 description 72
- 208000036142 Viral infection Diseases 0.000 description 58
- 230000009385 viral infection Effects 0.000 description 58
- 238000011282 treatment Methods 0.000 description 55
- 208000015181 infectious disease Diseases 0.000 description 53
- 230000000694 effects Effects 0.000 description 45
- 230000006870 function Effects 0.000 description 45
- 150000007523 nucleic acids Chemical class 0.000 description 45
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 44
- 102000039446 nucleic acids Human genes 0.000 description 43
- 108020004707 nucleic acids Proteins 0.000 description 43
- 108700012411 TNFSF10 Proteins 0.000 description 42
- 102000005962 receptors Human genes 0.000 description 40
- 108020003175 receptors Proteins 0.000 description 40
- 239000003153 chemical reaction reagent Substances 0.000 description 39
- -1 IL1a Proteins 0.000 description 37
- 238000003556 assay Methods 0.000 description 37
- 239000012472 biological sample Substances 0.000 description 37
- 238000001514 detection method Methods 0.000 description 32
- 238000012360 testing method Methods 0.000 description 31
- 238000005259 measurement Methods 0.000 description 27
- 238000003745 diagnosis Methods 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 26
- 108010029485 Protein Isoforms Proteins 0.000 description 25
- 102000001708 Protein Isoforms Human genes 0.000 description 25
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 24
- 230000003993 interaction Effects 0.000 description 24
- 102000004190 Enzymes Human genes 0.000 description 23
- 108090000790 Enzymes Proteins 0.000 description 23
- 230000001580 bacterial effect Effects 0.000 description 23
- 229940088598 enzyme Drugs 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 23
- 241000894006 Bacteria Species 0.000 description 22
- 108060003951 Immunoglobulin Proteins 0.000 description 22
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 22
- 238000006467 substitution reaction Methods 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 102000018358 immunoglobulin Human genes 0.000 description 21
- 238000013518 transcription Methods 0.000 description 21
- 230000035897 transcription Effects 0.000 description 21
- 102100032752 C-reactive protein Human genes 0.000 description 20
- 102100026236 Interleukin-8 Human genes 0.000 description 20
- 108090001007 Interleukin-8 Proteins 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 20
- 238000004132 cross linking Methods 0.000 description 20
- 230000035772 mutation Effects 0.000 description 20
- 230000004913 activation Effects 0.000 description 19
- 239000003242 anti bacterial agent Substances 0.000 description 19
- 239000012634 fragment Substances 0.000 description 19
- 108090000695 Cytokines Proteins 0.000 description 18
- 102000004890 Interleukin-8 Human genes 0.000 description 18
- AVIZABGQXBMRCJ-UHFFFAOYSA-N Mammea A/AB cyclo F Chemical compound C12=C(O)C(C(=O)C(C)CC)=C3OC(C(C)(C)O)CC3=C2OC(=O)C=C1C1=CC=CC=C1 AVIZABGQXBMRCJ-UHFFFAOYSA-N 0.000 description 18
- 210000004698 lymphocyte Anatomy 0.000 description 18
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 18
- 102000004127 Cytokines Human genes 0.000 description 17
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 17
- 108091006374 cAMP receptor proteins Proteins 0.000 description 17
- 230000008569 process Effects 0.000 description 17
- 230000035945 sensitivity Effects 0.000 description 17
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 16
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 16
- 102100027266 Ubiquitin-like protein ISG15 Human genes 0.000 description 16
- 229940088710 antibiotic agent Drugs 0.000 description 16
- 239000000090 biomarker Substances 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 102100038196 Chitinase-3-like protein 1 Human genes 0.000 description 15
- 101001057508 Homo sapiens Ubiquitin-like protein ISG15 Proteins 0.000 description 15
- 108010048233 Procalcitonin Proteins 0.000 description 15
- 239000012190 activator Substances 0.000 description 15
- 230000003115 biocidal effect Effects 0.000 description 15
- 238000011534 incubation Methods 0.000 description 15
- 210000001616 monocyte Anatomy 0.000 description 15
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 15
- 239000013598 vector Substances 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 14
- 230000001419 dependent effect Effects 0.000 description 14
- 230000018109 developmental process Effects 0.000 description 14
- 208000035473 Communicable disease Diseases 0.000 description 13
- 238000011161 development Methods 0.000 description 13
- 238000003780 insertion Methods 0.000 description 13
- 230000037431 insertion Effects 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 108700024394 Exon Proteins 0.000 description 12
- 102100026016 Interleukin-1 receptor type 1 Human genes 0.000 description 12
- 230000006907 apoptotic process Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 11
- 125000000539 amino acid group Chemical group 0.000 description 11
- 210000003719 b-lymphocyte Anatomy 0.000 description 11
- 230000004071 biological effect Effects 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 11
- 229920006008 lipopolysaccharide Polymers 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 10
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 10
- 108010066813 Chitinase-3-Like Protein 1 Proteins 0.000 description 10
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 10
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 10
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 230000000840 anti-viral effect Effects 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 238000003018 immunoassay Methods 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 238000012544 monitoring process Methods 0.000 description 10
- 230000017854 proteolysis Effects 0.000 description 10
- 230000011664 signaling Effects 0.000 description 10
- AVIZABGQXBMRCJ-DYVFJYSZSA-N 1,2-Dihydro-5-hydroxy-2-(1-hydroxy-1-methylethyl)-4-(2-methylbutyryl)-6-phenylfurano[2,3-h][1]benzopyran-8-one Natural products O=C([C@@H](CC)C)c1c(O)c2C(c3ccccc3)=CC(=O)Oc2c2c1O[C@H](C(O)(C)C)C2 AVIZABGQXBMRCJ-DYVFJYSZSA-N 0.000 description 9
- 101100344898 Arabidopsis thaliana MED13 gene Proteins 0.000 description 9
- 101100350216 Arabidopsis thaliana PDH2 gene Proteins 0.000 description 9
- 101100075829 Caenorhabditis elegans mab-3 gene Proteins 0.000 description 9
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000012875 competitive assay Methods 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 8
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 8
- 108010075704 HLA-A Antigens Proteins 0.000 description 8
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 8
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 description 8
- 102000014150 Interferons Human genes 0.000 description 8
- 108010050904 Interferons Proteins 0.000 description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
- 102100038805 Lysophospholipid acyltransferase 2 Human genes 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 102100029216 SLAM family member 5 Human genes 0.000 description 8
- 102100029681 Triggering receptor expressed on myeloid cells 1 Human genes 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 230000009824 affinity maturation Effects 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 229940079322 interferon Drugs 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 102000054765 polymorphisms of proteins Human genes 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 102100033497 Adiponectin receptor protein 1 Human genes 0.000 description 7
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 7
- 102000004354 CD11b Antigen Human genes 0.000 description 7
- 108010017009 CD11b Antigen Proteins 0.000 description 7
- 102000019034 Chemokines Human genes 0.000 description 7
- 108010012236 Chemokines Proteins 0.000 description 7
- 208000003322 Coinfection Diseases 0.000 description 7
- 239000004971 Cross linker Substances 0.000 description 7
- 102100040510 Galectin-3-binding protein Human genes 0.000 description 7
- 101001135206 Homo sapiens Adiponectin receptor protein 1 Proteins 0.000 description 7
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 7
- 101000727462 Homo sapiens Reticulon-3 Proteins 0.000 description 7
- 102000018697 Membrane Proteins Human genes 0.000 description 7
- 108010052285 Membrane Proteins Proteins 0.000 description 7
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 7
- 102100029832 Reticulon-3 Human genes 0.000 description 7
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 7
- 238000004422 calculation algorithm Methods 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 7
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 7
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 7
- 238000010606 normalization Methods 0.000 description 7
- 238000002823 phage display Methods 0.000 description 7
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- 230000002103 transcriptional effect Effects 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 102100022464 5'-nucleotidase Human genes 0.000 description 6
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical group C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 description 6
- 102100023688 Eotaxin Human genes 0.000 description 6
- 101710139422 Eotaxin Proteins 0.000 description 6
- 102100030341 Ethanolaminephosphotransferase 1 Human genes 0.000 description 6
- 102000003886 Glycoproteins Human genes 0.000 description 6
- 108090000288 Glycoproteins Proteins 0.000 description 6
- 101710121996 Hexon protein p72 Proteins 0.000 description 6
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 6
- 101000916059 Homo sapiens C-X-C chemokine receptor type 2 Proteins 0.000 description 6
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 6
- 101000804865 Homo sapiens E3 ubiquitin-protein ligase XIAP Proteins 0.000 description 6
- 101000967904 Homo sapiens Galectin-3-binding protein Proteins 0.000 description 6
- 101000663639 Homo sapiens Kunitz-type protease inhibitor 2 Proteins 0.000 description 6
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 6
- 101000589301 Homo sapiens Natural cytotoxicity triggering receptor 1 Proteins 0.000 description 6
- 101000589307 Homo sapiens Natural cytotoxicity triggering receptor 3 Proteins 0.000 description 6
- 101000857759 Homo sapiens Probable G-protein coupled receptor 162 Proteins 0.000 description 6
- 101000584600 Homo sapiens Ras-related protein Rap-1b Proteins 0.000 description 6
- 101100172525 Homo sapiens SELENOI gene Proteins 0.000 description 6
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 6
- 101000942626 Homo sapiens UMP-CMP kinase 2, mitochondrial Proteins 0.000 description 6
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 102100039020 Kunitz-type protease inhibitor 2 Human genes 0.000 description 6
- 102100033467 L-selectin Human genes 0.000 description 6
- 101710125418 Major capsid protein Proteins 0.000 description 6
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 6
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 6
- 102100035488 Nectin-2 Human genes 0.000 description 6
- 102000048238 Neuregulin-1 Human genes 0.000 description 6
- 108090000556 Neuregulin-1 Proteins 0.000 description 6
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 6
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 6
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 6
- 102100025358 Probable G-protein coupled receptor 162 Human genes 0.000 description 6
- 102100030705 Ras-related protein Rap-1b Human genes 0.000 description 6
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 6
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 6
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 6
- 102100032947 UMP-CMP kinase 2, mitochondrial Human genes 0.000 description 6
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 230000001086 cytosolic effect Effects 0.000 description 6
- 238000010494 dissociation reaction Methods 0.000 description 6
- 230000005593 dissociations Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 102000006495 integrins Human genes 0.000 description 6
- 108010044426 integrins Proteins 0.000 description 6
- 229940096397 interleukin-8 Drugs 0.000 description 6
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000007620 mathematical function Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000005012 migration Effects 0.000 description 6
- 238000013508 migration Methods 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 231100000350 mutagenesis Toxicity 0.000 description 6
- 239000002516 radical scavenger Substances 0.000 description 6
- 125000006853 reporter group Chemical group 0.000 description 6
- 102000030938 small GTPase Human genes 0.000 description 6
- 108060007624 small GTPase Proteins 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 230000009870 specific binding Effects 0.000 description 6
- 238000012706 support-vector machine Methods 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 5
- YMZPQKXPKZZSFV-CPWYAANMSA-N 2-[3-[(1r)-1-[(2s)-1-[(2s)-2-[(1r)-cyclohex-2-en-1-yl]-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carbonyl]oxy-3-(3,4-dimethoxyphenyl)propyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H]([C@H]2C=CCCC2)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 YMZPQKXPKZZSFV-CPWYAANMSA-N 0.000 description 5
- GTVAUHXUMYENSK-RWSKJCERSA-N 2-[3-[(1r)-3-(3,4-dimethoxyphenyl)-1-[(2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC=C)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GTVAUHXUMYENSK-RWSKJCERSA-N 0.000 description 5
- 102100038008 60S ribosomal protein L22-like 1 Human genes 0.000 description 5
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
- 102100031786 Adiponectin Human genes 0.000 description 5
- PCLCDPVEEFVAAQ-UHFFFAOYSA-N BCA 1 Chemical compound CC(CO)CCCC(C)C1=CCC(C)(O)C1CC2=C(O)C(O)CCC2=O PCLCDPVEEFVAAQ-UHFFFAOYSA-N 0.000 description 5
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 5
- 101710098272 C-X-C motif chemokine 11 Proteins 0.000 description 5
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 5
- 102100041022 Coronin-1C Human genes 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 102100029602 Eukaryotic translation initiation factor 4B Human genes 0.000 description 5
- 102100031493 Growth arrest-specific protein 7 Human genes 0.000 description 5
- 101000661567 Homo sapiens 60S ribosomal protein L22-like 1 Proteins 0.000 description 5
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 5
- 101000748856 Homo sapiens Coronin-1C Proteins 0.000 description 5
- 101000840282 Homo sapiens Eukaryotic translation initiation factor 4B Proteins 0.000 description 5
- 101000923044 Homo sapiens Growth arrest-specific protein 7 Proteins 0.000 description 5
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 5
- 101001128393 Homo sapiens Interferon-induced GTP-binding protein Mx1 Proteins 0.000 description 5
- 101001082065 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 description 5
- 101001082060 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 3 Proteins 0.000 description 5
- 101001034844 Homo sapiens Interferon-induced transmembrane protein 1 Proteins 0.000 description 5
- 101001034846 Homo sapiens Interferon-induced transmembrane protein 3 Proteins 0.000 description 5
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 5
- 101000657037 Homo sapiens Radical S-adenosyl methionine domain-containing protein 2 Proteins 0.000 description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 5
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 5
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 5
- 102100032818 Integrin alpha-4 Human genes 0.000 description 5
- 102100031802 Interferon-induced GTP-binding protein Mx1 Human genes 0.000 description 5
- 102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 description 5
- 102100027302 Interferon-induced protein with tetratricopeptide repeats 3 Human genes 0.000 description 5
- 102100040021 Interferon-induced transmembrane protein 1 Human genes 0.000 description 5
- 102100040035 Interferon-induced transmembrane protein 3 Human genes 0.000 description 5
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 5
- 102000000704 Interleukin-7 Human genes 0.000 description 5
- 108010002586 Interleukin-7 Proteins 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 102100024573 Macrophage-capping protein Human genes 0.000 description 5
- 108010003541 Platelet Activating Factor Proteins 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 102100033749 Radical S-adenosyl methionine domain-containing protein 2 Human genes 0.000 description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 5
- 102100040952 Tetraspanin-7 Human genes 0.000 description 5
- 108010066451 Triggering Receptor Expressed on Myeloid Cells-1 Proteins 0.000 description 5
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 5
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 5
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 5
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000003431 cross linking reagent Substances 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 210000003979 eosinophil Anatomy 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 239000000833 heterodimer Substances 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000013507 mapping Methods 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002703 mutagenesis Methods 0.000 description 5
- 230000009871 nonspecific binding Effects 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 238000007637 random forest analysis Methods 0.000 description 5
- 230000008707 rearrangement Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 238000011272 standard treatment Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 102100027621 2'-5'-oligoadenylate synthase 2 Human genes 0.000 description 4
- PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 description 4
- 108010076365 Adiponectin Proteins 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- 241000351920 Aspergillus nidulans Species 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 101800001318 Capsid protein VP4 Proteins 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 102000010170 Death domains Human genes 0.000 description 4
- 108050001718 Death domains Proteins 0.000 description 4
- 102100034597 E3 ubiquitin-protein ligase TRIM22 Human genes 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 4
- 108091006109 GTPases Proteins 0.000 description 4
- 101001008910 Homo sapiens 2'-5'-oligoadenylate synthase 2 Proteins 0.000 description 4
- 101000848629 Homo sapiens E3 ubiquitin-protein ligase TRIM22 Proteins 0.000 description 4
- 101000957316 Homo sapiens Lysophospholipid acyltransferase 2 Proteins 0.000 description 4
- 101001109719 Homo sapiens Nucleophosmin Proteins 0.000 description 4
- 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 4
- 101000964436 Homo sapiens Z-DNA-binding protein 1 Proteins 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 4
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 4
- 102100030607 Mothers against decapentaplegic homolog 9 Human genes 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108091005461 Nucleic proteins Proteins 0.000 description 4
- 102100022678 Nucleophosmin Human genes 0.000 description 4
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 4
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 4
- 101700031501 SMAD9 Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 101150043341 Socs3 gene Proteins 0.000 description 4
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 4
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 description 4
- 102100024283 Suppressor of cytokine signaling 3 Human genes 0.000 description 4
- 102100037219 Syntenin-1 Human genes 0.000 description 4
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 241000710886 West Nile virus Species 0.000 description 4
- 102100040310 Z-DNA-binding protein 1 Human genes 0.000 description 4
- BAWFJGJZGIEFAR-DQQFMEOOSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)O[P@@](O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-DQQFMEOOSA-N 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 230000008472 epithelial growth Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 108091008053 gene clusters Proteins 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000015788 innate immune response Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 229940100994 interleukin-7 Drugs 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 102000016914 ras Proteins Human genes 0.000 description 4
- 108010014186 ras Proteins Proteins 0.000 description 4
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 4
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 4
- 239000012925 reference material Substances 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 4
- 108010052187 1-Acylglycerophosphocholine O-Acyltransferase Proteins 0.000 description 3
- 102100021636 Actin-related protein 2/3 complex subunit 2 Human genes 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 3
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 3
- 102100040432 Ankyrin repeat and BTB/POZ domain-containing protein 1 Human genes 0.000 description 3
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 3
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 3
- 108010074051 C-Reactive Protein Proteins 0.000 description 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 3
- 108050006947 CXC Chemokine Proteins 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 102000012286 Chitinases Human genes 0.000 description 3
- 108010022172 Chitinases Proteins 0.000 description 3
- OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 3
- 241000255925 Diptera Species 0.000 description 3
- 102100039621 Epithelial-stromal interaction protein 1 Human genes 0.000 description 3
- 102000016955 Erythrocyte Anion Exchange Protein 1 Human genes 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 3
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 3
- 108010058607 HLA-B Antigens Proteins 0.000 description 3
- 108010052199 HLA-C Antigens Proteins 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 101000754220 Homo sapiens Actin-related protein 2/3 complex subunit 2 Proteins 0.000 description 3
- 101000964352 Homo sapiens Ankyrin repeat and BTB/POZ domain-containing protein 1 Proteins 0.000 description 3
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 3
- 101000814134 Homo sapiens Epithelial-stromal interaction protein 1 Proteins 0.000 description 3
- 101000625192 Homo sapiens Glutamine-tRNA ligase Proteins 0.000 description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 3
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 3
- 101001005211 Homo sapiens Lipoyltransferase 1, mitochondrial Proteins 0.000 description 3
- 101000938676 Homo sapiens Liver carboxylesterase 1 Proteins 0.000 description 3
- 101001065568 Homo sapiens Lymphocyte antigen 6E Proteins 0.000 description 3
- 101000630284 Homo sapiens Proline-tRNA ligase Proteins 0.000 description 3
- 101001098769 Homo sapiens Protein disulfide-isomerase A6 Proteins 0.000 description 3
- 101000613617 Homo sapiens Protein mono-ADP-ribosyltransferase PARP12 Proteins 0.000 description 3
- 101000735459 Homo sapiens Protein mono-ADP-ribosyltransferase PARP9 Proteins 0.000 description 3
- 101000620529 Homo sapiens Ras-related protein Rab-13 Proteins 0.000 description 3
- 101001060862 Homo sapiens Ras-related protein Rab-31 Proteins 0.000 description 3
- 101000856696 Homo sapiens Rho GDP-dissociation inhibitor 2 Proteins 0.000 description 3
- 101000740523 Homo sapiens Syntenin-1 Proteins 0.000 description 3
- 101000795107 Homo sapiens Triggering receptor expressed on myeloid cells 1 Proteins 0.000 description 3
- 101000644684 Homo sapiens Ubiquitin-conjugating enzyme E2 N Proteins 0.000 description 3
- 101000954434 Homo sapiens V-type proton ATPase 21 kDa proteolipid subunit c'' Proteins 0.000 description 3
- 101000814514 Homo sapiens XIAP-associated factor 1 Proteins 0.000 description 3
- 101000823782 Homo sapiens Y-box-binding protein 3 Proteins 0.000 description 3
- 101001129796 Homo sapiens p53-induced death domain-containing protein 1 Proteins 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102100022118 Leukotriene A-4 hydrolase Human genes 0.000 description 3
- 102100025853 Lipoyltransferase 1, mitochondrial Human genes 0.000 description 3
- 102100032131 Lymphocyte antigen 6E Human genes 0.000 description 3
- 101710097496 Lysophospholipid acyltransferase Proteins 0.000 description 3
- 101710163746 Lysophospholipid acyltransferase 2 Proteins 0.000 description 3
- 102100031347 Metallothionein-2 Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 102100026126 Proline-tRNA ligase Human genes 0.000 description 3
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 3
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 3
- 102100037061 Protein disulfide-isomerase A6 Human genes 0.000 description 3
- 102100040845 Protein mono-ADP-ribosyltransferase PARP12 Human genes 0.000 description 3
- 102100034930 Protein mono-ADP-ribosyltransferase PARP9 Human genes 0.000 description 3
- 102100022303 Ras-related protein Rab-13 Human genes 0.000 description 3
- 102100027838 Ras-related protein Rab-31 Human genes 0.000 description 3
- 101000599776 Rattus norvegicus Insulin-like growth factor 2 mRNA-binding protein 1 Proteins 0.000 description 3
- 102100025622 Rho GDP-dissociation inhibitor 2 Human genes 0.000 description 3
- 108010000605 Ribosomal Proteins Proteins 0.000 description 3
- 102000002278 Ribosomal Proteins Human genes 0.000 description 3
- 102100027720 SH2 domain-containing protein 1A Human genes 0.000 description 3
- 108091006318 SLC4A1 Proteins 0.000 description 3
- 101710190759 Serum amyloid A protein Proteins 0.000 description 3
- 102100032277 Serum amyloid A-1 protein Human genes 0.000 description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 101710120037 Toxin CcdB Proteins 0.000 description 3
- 108090000848 Ubiquitin Proteins 0.000 description 3
- 102000044159 Ubiquitin Human genes 0.000 description 3
- 102100020695 Ubiquitin-conjugating enzyme E2 N Human genes 0.000 description 3
- 102100037167 V-type proton ATPase 21 kDa proteolipid subunit c'' Human genes 0.000 description 3
- 102100039488 XIAP-associated factor 1 Human genes 0.000 description 3
- 102100022221 Y-box-binding protein 3 Human genes 0.000 description 3
- 108091027569 Z-DNA Proteins 0.000 description 3
- 238000012867 alanine scanning Methods 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 229940112869 bone morphogenetic protein Drugs 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 230000033077 cellular process Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000005482 chemotactic factor Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 108010004073 cysteinylcysteine Proteins 0.000 description 3
- 230000005860 defense response to virus Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000008611 intercellular interaction Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- UFPQIRYSPUYQHK-WAQVJNLQSA-N leukotriene A4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@@H]1O[C@H]1CCCC(O)=O UFPQIRYSPUYQHK-WAQVJNLQSA-N 0.000 description 3
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 3
- 235000019136 lipoic acid Nutrition 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 102100031691 p53-induced death domain-containing protein 1 Human genes 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 150000003905 phosphatidylinositols Chemical class 0.000 description 3
- 108091005981 phosphorylated proteins Proteins 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229960002663 thioctic acid Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 102000035160 transmembrane proteins Human genes 0.000 description 3
- 108091005703 transmembrane proteins Proteins 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- 102000018659 1-Acylglycerophosphocholine O-Acyltransferase Human genes 0.000 description 2
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 2
- NCMVOABPESMRCP-SHYZEUOFSA-N 2'-deoxycytosine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 NCMVOABPESMRCP-SHYZEUOFSA-N 0.000 description 2
- 102100040637 60S ribosomal protein L34 Human genes 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- 241000256173 Aedes albopictus Species 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 102000007592 Apolipoproteins Human genes 0.000 description 2
- 108010071619 Apolipoproteins Proteins 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 101100325788 Arabidopsis thaliana BCA1 gene Proteins 0.000 description 2
- 101100503323 Artemisia annua FPS1 gene Proteins 0.000 description 2
- 108091012583 BCL2 Proteins 0.000 description 2
- 241000194108 Bacillus licheniformis Species 0.000 description 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 2
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 2
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 2
- 102000039968 CEA family Human genes 0.000 description 2
- 108091069214 CEA family Proteins 0.000 description 2
- 102000019388 CXC chemokine Human genes 0.000 description 2
- 108010061298 CXCR5 Receptors Proteins 0.000 description 2
- 102000004631 Calcineurin Human genes 0.000 description 2
- 108010042955 Calcineurin Proteins 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 101001110283 Canis lupus familiaris Ras-related C3 botulinum toxin substrate 1 Proteins 0.000 description 2
- 102100038712 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1 Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102100026548 Caspase-8 Human genes 0.000 description 2
- 108090000538 Caspase-8 Proteins 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010078015 Complement C3b Proteins 0.000 description 2
- 102100028233 Coronin-1A Human genes 0.000 description 2
- 101100232684 Cryptosporidium parvum EIF4-A gene Proteins 0.000 description 2
- 102000036364 Cullin Ring E3 Ligases Human genes 0.000 description 2
- 108091007045 Cullin Ring E3 Ligases Proteins 0.000 description 2
- 102100026234 Cytokine receptor common subunit gamma Human genes 0.000 description 2
- 101150097493 D gene Proteins 0.000 description 2
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000255601 Drosophila melanogaster Species 0.000 description 2
- 102100039922 E3 ISG15-protein ligase HERC5 Human genes 0.000 description 2
- 101710196841 Erythrocyte-binding antigen 175 Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 2
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 2
- 102000013382 Gelatinases Human genes 0.000 description 2
- 108010026132 Gelatinases Proteins 0.000 description 2
- 101100503326 Gibberella fujikuroi FPPS gene Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 102100035716 Glycophorin-A Human genes 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 2
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 101000672659 Homo sapiens 60S ribosomal protein L34 Proteins 0.000 description 2
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 2
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 2
- 101100222383 Homo sapiens CXCL13 gene Proteins 0.000 description 2
- 101000883304 Homo sapiens Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1 Proteins 0.000 description 2
- 101000860852 Homo sapiens Coronin-1A Proteins 0.000 description 2
- 101001055227 Homo sapiens Cytokine receptor common subunit gamma Proteins 0.000 description 2
- 101001035145 Homo sapiens E3 ISG15-protein ligase HERC5 Proteins 0.000 description 2
- 101001074244 Homo sapiens Glycophorin-A Proteins 0.000 description 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 2
- 101001082070 Homo sapiens Interferon alpha-inducible protein 6 Proteins 0.000 description 2
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 description 2
- 101000619898 Homo sapiens Leukotriene A-4 hydrolase Proteins 0.000 description 2
- 101000615941 Homo sapiens Mannosyl-oligosaccharide 1,2-alpha-mannosidase IC Proteins 0.000 description 2
- 101001110313 Homo sapiens Ras-related C3 botulinum toxin substrate 2 Proteins 0.000 description 2
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 2
- 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 description 2
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108060004056 Integrin alpha Chain Proteins 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 102100027354 Interferon alpha-inducible protein 6 Human genes 0.000 description 2
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 101710089751 Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- 108050001109 Interleukin-1 receptor type 1 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102100025837 JNK1/MAPK8-associated membrane protein Human genes 0.000 description 2
- 101710176060 JNK1/MAPK8-associated membrane protein Proteins 0.000 description 2
- UFPQIRYSPUYQHK-VRKJBCFNSA-N Leukotriene A4 Natural products CCCCCC=C/CC=C/C=C/C=C/[C@@H]1O[C@H]1CCCC(=O)O UFPQIRYSPUYQHK-VRKJBCFNSA-N 0.000 description 2
- 101710163717 Lysophospholipid acyltransferase 5 Proteins 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 108010054377 Mannosidases Proteins 0.000 description 2
- 102000001696 Mannosidases Human genes 0.000 description 2
- 102100021770 Mannosyl-oligosaccharide 1,2-alpha-mannosidase IC Human genes 0.000 description 2
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000031662 Noncommunicable disease Diseases 0.000 description 2
- 239000012661 PARP inhibitor Substances 0.000 description 2
- 101800001442 Peptide pr Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical group OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
- 102100022129 Ras-related C3 botulinum toxin substrate 2 Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108091006647 SLC9A1 Proteins 0.000 description 2
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 2
- 241001123650 Schwanniomyces occidentalis Species 0.000 description 2
- 108010074686 Selenoproteins Proteins 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 241000607720 Serratia Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010002687 Survivin Proteins 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 description 2
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 description 2
- 102000018686 U4-U6 Small Nuclear Ribonucleoprotein Human genes 0.000 description 2
- 108010091808 U4-U6 Small Nuclear Ribonucleoprotein Proteins 0.000 description 2
- 101150117115 V gene Proteins 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical group OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000009833 antibody interaction Effects 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 230000004094 calcium homeostasis Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 238000007635 classification algorithm Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000002790 cross-validation Methods 0.000 description 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229950008963 emoctakin Drugs 0.000 description 2
- 239000003532 endogenous pyrogen Substances 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 208000001786 gonorrhea Diseases 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 244000052637 human pathogen Species 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 102000017777 integrin alpha chain Human genes 0.000 description 2
- 238000012482 interaction analysis Methods 0.000 description 2
- 230000009878 intermolecular interaction Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- 108010052620 leukocyte endogenous mediator Proteins 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 108010009689 mannosyl-oligosaccharide 1,2-alpha-mannosidase Proteins 0.000 description 2
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 210000000680 phagosome Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108020003519 protein disulfide isomerase Proteins 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 229940055619 selenocysteine Drugs 0.000 description 2
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 2
- 235000016491 selenocysteine Nutrition 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 2
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 208000023516 stroke disease Diseases 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 210000002437 synoviocyte Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001578 tight junction Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 230000028973 vesicle-mediated transport Effects 0.000 description 2
- 230000007486 viral budding Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- IXDZFGATLNCIOI-NGJCXOISSA-N (3r,4r,5r)-3,4,5,6-tetrahydroxyhexan-2-one Chemical compound CC(=O)[C@H](O)[C@H](O)[C@H](O)CO IXDZFGATLNCIOI-NGJCXOISSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- KFEUJDWYNGMDBV-UHFFFAOYSA-N (N-Acetyl)-glucosamin-4-beta-galaktosid Natural products OC1C(NC(=O)C)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 KFEUJDWYNGMDBV-UHFFFAOYSA-N 0.000 description 1
- HKWJHKSHEWVOSS-OMDJCSNQSA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O HKWJHKSHEWVOSS-OMDJCSNQSA-N 0.000 description 1
- WDCYWAQPCXBPJA-UHFFFAOYSA-N 1,3-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC([N+]([O-])=O)=C1 WDCYWAQPCXBPJA-UHFFFAOYSA-N 0.000 description 1
- CWRILEGKIAOYKP-SSDOTTSWSA-N 1-acyl-sn-glycero-3-phosphoethanolamine Chemical compound CC(=O)OC[C@@H](O)COP(O)(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-N 0.000 description 1
- 101710124165 1-acyl-sn-glycerol-3-phosphate acyltransferase Proteins 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 102000041002 2-5A synthase family Human genes 0.000 description 1
- 108091060610 2-5A synthase family Proteins 0.000 description 1
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 1
- 108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- CFWRDBDJAOHXSH-UHFFFAOYSA-N 2-azaniumylethyl 2,3-diacetyloxypropyl phosphate Chemical compound CC(=O)OCC(OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 101150051089 A3 gene Proteins 0.000 description 1
- 101150112998 ADIPOQ gene Proteins 0.000 description 1
- 101150096655 APM1 gene Proteins 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 102000004373 Actin-related protein 2 Human genes 0.000 description 1
- 108090000963 Actin-related protein 2 Proteins 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 101710152920 AdoMet-dependent rRNA methyltransferase SPB1 Proteins 0.000 description 1
- 241000256111 Aedes <genus> Species 0.000 description 1
- XZWXFWBHYRFLEF-FSPLSTOPSA-N Ala-His Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 XZWXFWBHYRFLEF-FSPLSTOPSA-N 0.000 description 1
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
- YYAVDNKUWLAFCV-ACZMJKKPSA-N Ala-Ser-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O YYAVDNKUWLAFCV-ACZMJKKPSA-N 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000001049 Amyloid Human genes 0.000 description 1
- 108010094108 Amyloid Proteins 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 1
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- 102100027308 Apoptosis regulator BAX Human genes 0.000 description 1
- SIFXMYAHXJGAFC-WDSKDSINSA-N Arg-Asp Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O SIFXMYAHXJGAFC-WDSKDSINSA-N 0.000 description 1
- QYLJIYOGHRGUIH-CIUDSAMLSA-N Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N QYLJIYOGHRGUIH-CIUDSAMLSA-N 0.000 description 1
- PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
- IIFDPDVJAHQFSR-WHFBIAKZSA-N Asn-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O IIFDPDVJAHQFSR-WHFBIAKZSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 102000008836 BTB/POZ domains Human genes 0.000 description 1
- 108050000749 BTB/POZ domains Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101100002068 Bacillus subtilis (strain 168) araR gene Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102100021257 Beta-secretase 1 Human genes 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- ODZBBRURCPAEIQ-DJLDLDEBSA-N Brivudine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=CBr)=C1 ODZBBRURCPAEIQ-DJLDLDEBSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- HIBWGGKDGCBPTA-UHFFFAOYSA-N C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 HIBWGGKDGCBPTA-UHFFFAOYSA-N 0.000 description 1
- 108010062802 CD66 antigens Proteins 0.000 description 1
- IERHLVCPSMICTF-XVFCMESISA-N CMP group Chemical group P(=O)(O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C(=O)N=C(N)C=C1)O)O IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 1
- 102100029761 Cadherin-5 Human genes 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000710190 Cardiovirus Species 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108050001186 Chaperonin Cpn60 Proteins 0.000 description 1
- 102000052603 Chaperonins Human genes 0.000 description 1
- 108010014419 Chemokine CXCL1 Proteins 0.000 description 1
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 1
- 108010008978 Chemokine CXCL10 Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- NMPOSNRHZIWLLL-XUWVNRHRSA-N Cocaethylene Chemical group O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OCC)C(=O)C1=CC=CC=C1 NMPOSNRHZIWLLL-XUWVNRHRSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 101100162826 Dictyostelium discoideum apm2 gene Proteins 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108700022174 Drosophila Son of Sevenless Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000043859 Dynamin Human genes 0.000 description 1
- 108700021058 Dynamin Proteins 0.000 description 1
- 102100029944 E3 ubiquitin-protein ligase SHPRH Human genes 0.000 description 1
- 230000008341 ER-associated protein catabolic process Effects 0.000 description 1
- PHMBVCPLDPDESM-YWIQKCBGSA-N Ecgonine Natural products C1[C@H](O)[C@@H](C(O)=O)[C@H]2CC[C@@H]1N2C PHMBVCPLDPDESM-YWIQKCBGSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010003751 Elongin Proteins 0.000 description 1
- 102000004662 Elongin Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 206010014909 Enterovirus infection Diseases 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 101100155952 Escherichia coli (strain K12) uvrD gene Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000003782 Eukaryotic Initiation Factor-4F Human genes 0.000 description 1
- 108010057194 Eukaryotic Initiation Factor-4F Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 102100021736 Galectin-1 Human genes 0.000 description 1
- 101710197901 Galectin-3-binding protein Proteins 0.000 description 1
- 108010046569 Galectins Proteins 0.000 description 1
- 102000007563 Galectins Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQWMZOIPXWSZNE-WDSKDSINSA-N Gln-Asp-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O WQWMZOIPXWSZNE-WDSKDSINSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100033067 Growth factor receptor-bound protein 2 Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 1
- 102100027489 Helicase-like transcription factor Human genes 0.000 description 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000018754 Histone Chaperones Human genes 0.000 description 1
- 108010052497 Histone Chaperones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 101000684275 Homo sapiens ADP-ribosylation factor 3 Proteins 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101100437218 Homo sapiens B2M gene Proteins 0.000 description 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 1
- 101000794587 Homo sapiens Cadherin-5 Proteins 0.000 description 1
- 101000981093 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 1 Proteins 0.000 description 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 1
- 101000863869 Homo sapiens E3 ubiquitin-protein ligase SHPRH Proteins 0.000 description 1
- 101000926530 Homo sapiens Eukaryotic translation initiation factor 2-alpha kinase 1 Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000871017 Homo sapiens Growth factor receptor-bound protein 2 Proteins 0.000 description 1
- 101001081105 Homo sapiens Helicase-like transcription factor Proteins 0.000 description 1
- 101001055314 Homo sapiens Immunoglobulin heavy constant alpha 2 Proteins 0.000 description 1
- 101001055308 Homo sapiens Immunoglobulin heavy constant epsilon Proteins 0.000 description 1
- 101000961156 Homo sapiens Immunoglobulin heavy constant gamma 1 Proteins 0.000 description 1
- 101000961146 Homo sapiens Immunoglobulin heavy constant gamma 2 Proteins 0.000 description 1
- 101000961145 Homo sapiens Immunoglobulin heavy constant gamma 3 Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001034842 Homo sapiens Interferon-induced transmembrane protein 2 Proteins 0.000 description 1
- 101000960936 Homo sapiens Interleukin-5 receptor subunit alpha Proteins 0.000 description 1
- 101000599056 Homo sapiens Interleukin-6 receptor subunit beta Proteins 0.000 description 1
- 101100455054 Homo sapiens LTA4H gene Proteins 0.000 description 1
- 101001052490 Homo sapiens Mitogen-activated protein kinase 3 Proteins 0.000 description 1
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 1
- 101001135199 Homo sapiens Partitioning defective 3 homolog Proteins 0.000 description 1
- 101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 description 1
- 101000655540 Homo sapiens Protransforming growth factor alpha Proteins 0.000 description 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 101001130437 Homo sapiens Ras-related protein Rap-2b Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101100053794 Homo sapiens ZBTB7C gene Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- JWBXCSQZLLIOCI-GUBZILKMSA-N Ile-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C JWBXCSQZLLIOCI-GUBZILKMSA-N 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102100026216 Immunoglobulin heavy constant alpha 2 Human genes 0.000 description 1
- 102100039345 Immunoglobulin heavy constant gamma 1 Human genes 0.000 description 1
- 102100039346 Immunoglobulin heavy constant gamma 2 Human genes 0.000 description 1
- 102100039348 Immunoglobulin heavy constant gamma 3 Human genes 0.000 description 1
- CIPFCGZLFXVXBG-FTSGZOCFSA-N Inositol 1,3,4,5-tetraphosphate Chemical compound O[C@H]1C(OP(O)(O)=O)[C@H](O)[C@@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H]1OP(O)(O)=O CIPFCGZLFXVXBG-FTSGZOCFSA-N 0.000 description 1
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102100040020 Interferon-induced transmembrane protein 2 Human genes 0.000 description 1
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010038484 Interleukin-5 Receptors Proteins 0.000 description 1
- 102000010786 Interleukin-5 Receptors Human genes 0.000 description 1
- 102100039881 Interleukin-5 receptor subunit alpha Human genes 0.000 description 1
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 102000056028 KRIT1 Human genes 0.000 description 1
- 108700042464 KRIT1 Proteins 0.000 description 1
- 101150090242 KRIT1 gene Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- LCPYQJIKPJDLLB-UWVGGRQHSA-N Leu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C LCPYQJIKPJDLLB-UWVGGRQHSA-N 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- JPNRPAJITHRXRH-BQBZGAKWSA-N Lys-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O JPNRPAJITHRXRH-BQBZGAKWSA-N 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- DINOPBPYOCMGGD-VEDJBHDQSA-N Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)O3)O)O2)O)[C@@H](CO)O1 DINOPBPYOCMGGD-VEDJBHDQSA-N 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 108091092919 Minisatellite Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 101100533945 Mus musculus Serpina3g gene Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- HESSGHHCXGBPAJ-UHFFFAOYSA-N N-acetyllactosamine Natural products CC(=O)NC(C=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O HESSGHHCXGBPAJ-UHFFFAOYSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 101800003852 Neuropeptide F Proteins 0.000 description 1
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108010015832 Non-Receptor Type 2 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 102000000470 PDZ domains Human genes 0.000 description 1
- 108050008994 PDZ domains Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102100033496 Partitioning defective 3 homolog Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 1
- WEMYTDDMDBLPMI-DKIMLUQUSA-N Phe-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N WEMYTDDMDBLPMI-DKIMLUQUSA-N 0.000 description 1
- 101900101471 Plasmodium falciparum Erythrocyte-binding antigen 175 Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108010068086 Polyubiquitin Proteins 0.000 description 1
- 102100037935 Polyubiquitin-C Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710172946 Probable 1-acyl-sn-glycerol-3-phosphate acyltransferase Proteins 0.000 description 1
- 102100033344 Programmed cell death 6-interacting protein Human genes 0.000 description 1
- 108010049395 Prokaryotic Initiation Factor-2 Proteins 0.000 description 1
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 102100032350 Protransforming growth factor alpha Human genes 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101710113459 RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 101150020518 RHEB gene Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 102000056817 RNF5 Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000042022 Rab family Human genes 0.000 description 1
- 108091079902 Rab family Proteins 0.000 description 1
- 108700019578 Ras Homolog Enriched in Brain Proteins 0.000 description 1
- 102000046951 Ras Homolog Enriched in Brain Human genes 0.000 description 1
- 102100031421 Ras-related protein Rap-2b Human genes 0.000 description 1
- 101100411652 Rattus norvegicus Rrad gene Proteins 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 101100075025 Scheffersomyces stipitis (strain ATCC 58785 / CBS 6054 / NBRC 10063 / NRRL Y-11545) LTA4 gene Proteins 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 102000008114 Selenoproteins Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
- LZLREEUGSYITMX-JQWIXIFHSA-N Ser-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CO)N)C(O)=O)=CNC2=C1 LZLREEUGSYITMX-JQWIXIFHSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 1
- 108010011033 Signaling Lymphocytic Activation Molecule Associated Protein Proteins 0.000 description 1
- 102000013970 Signaling Lymphocytic Activation Molecule Associated Protein Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102100030980 Sodium/hydrogen exchanger 1 Human genes 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 108010083130 Syntenins Proteins 0.000 description 1
- 230000009809 T cell chemotaxis Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 102000002154 T-Lymphoma Invasion and Metastasis-inducing Protein 1 Human genes 0.000 description 1
- 108010001288 T-Lymphoma Invasion and Metastasis-inducing Protein 1 Proteins 0.000 description 1
- 108091085018 TGF-beta family Proteins 0.000 description 1
- 102000043168 TGF-beta family Human genes 0.000 description 1
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 1
- 102000003718 TNF receptor-associated factor 5 Human genes 0.000 description 1
- 108090000001 TNF receptor-associated factor 5 Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108700031126 Tetraspanins Proteins 0.000 description 1
- 102000043977 Tetraspanins Human genes 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 101710197991 Transcription factor SOX-4 Proteins 0.000 description 1
- 102100036693 Transcription factor SOX-4 Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 101710098580 Tubulin gamma-1 chain Proteins 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- VNYDHJARLHNEGA-RYUDHWBXSA-N Tyr-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 VNYDHJARLHNEGA-RYUDHWBXSA-N 0.000 description 1
- JAQGKXUEKGKTKX-HOTGVXAUSA-N Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 JAQGKXUEKGKTKX-HOTGVXAUSA-N 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102100033141 Tyrosine-protein phosphatase non-receptor type 2 Human genes 0.000 description 1
- 101710087750 Ubiquitin-like protein ISG15 Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- IBIDRSSEHFLGSD-YUMQZZPRSA-N Val-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-YUMQZZPRSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000010206 X-Linked Mental Retardation Diseases 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- FHHZHGZBHYYWTG-INFSMZHSSA-N [(2r,3s,4r,5r)-5-(2-amino-7-methyl-6-oxo-3h-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[[(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] phosphate Chemical compound N1C(N)=NC(=O)C2=C1[N+]([C@H]1[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=C(C(N=C(N)N4)=O)N=C3)O)O1)O)=CN2C FHHZHGZBHYYWTG-INFSMZHSSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 108010029777 actin interacting protein 1 Proteins 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- CMQZRJBJDCVIEY-JEOLMMCMSA-N alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)[C@@H]1NC(C)=O CMQZRJBJDCVIEY-JEOLMMCMSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000008262 antibiotic resistance mechanism Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 101150044616 araC gene Proteins 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 238000013476 bayesian approach Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 208000001969 capillary hemangioma Diseases 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000031154 cholesterol homeostasis Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000010224 classification analysis Methods 0.000 description 1
- 238000013145 classification model Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 210000002314 coated vesicle Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000025081 congenital sodium diarrhea Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036757 core body temperature Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 125000004122 cyclic group Chemical class 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 150000001945 cysteines Chemical group 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- PHMBVCPLDPDESM-UHFFFAOYSA-N d-Pseudoekgonin Natural products C1C(O)C(C(O)=O)C2CCC1N2C PHMBVCPLDPDESM-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 208000015355 drug-resistant tuberculosis Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 108010037623 eIF-2 Kinase Proteins 0.000 description 1
- PHMBVCPLDPDESM-FKSUSPILSA-N ecgonine Chemical compound C1[C@H](O)[C@H](C(O)=O)[C@H]2CC[C@@H]1N2C PHMBVCPLDPDESM-FKSUSPILSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000009483 enzymatic pathway Effects 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 208000036984 extensively drug-resistant tuberculosis Diseases 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 108010063260 fatty acyl ethyl ester synthase Proteins 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000009415 formwork Methods 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 150000008195 galaktosides Chemical class 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 230000006127 geranylation Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229920000550 glycopolymer Polymers 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 208000019408 hereditary arterial and articular multiple calcification syndrome Diseases 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000010057 immune-inflammatory process Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000003017 in situ immunoassay Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 108700032552 influenza virus INS1 Proteins 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 108010088383 interleukin-6 receptor alpha Proteins 0.000 description 1
- 108010038415 interleukin-8 receptors Proteins 0.000 description 1
- 102000010681 interleukin-8 receptors Human genes 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000000503 lectinlike effect Effects 0.000 description 1
- 102000005861 leptin receptors Human genes 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 210000004901 leucine-rich repeat Anatomy 0.000 description 1
- 108010091798 leucylleucine Proteins 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000022288 lymphocyte chemotaxis Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000022275 macrophage chemotaxis Effects 0.000 description 1
- 108091005446 macrophage receptors Proteins 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 108010083819 mannosyl-oligosaccharide 1,3 - 1,6-alpha-mannosidase Proteins 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000004492 methyl ester group Chemical group 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000005776 mitochondrial apoptotic pathway Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000947 motile cell Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000010353 neuronal integration Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 108010028584 nucleotidase Proteins 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002924 oxiranes Chemical group 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 102000041715 pentraxin family Human genes 0.000 description 1
- 108091075331 pentraxin family Proteins 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 230000011340 peptidyl-tyrosine autophosphorylation Effects 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WFLQAMUOBIONDG-UHFFFAOYSA-N phenoxyarsonic acid Chemical compound O[As](O)(=O)OC1=CC=CC=C1 WFLQAMUOBIONDG-UHFFFAOYSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003910 phosphatidylinositol 3-phosphates Chemical class 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 210000002729 polyribosome Anatomy 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 108091008077 processed pseudogenes Proteins 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000013197 protein A assay Methods 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 238000000455 protein structure prediction Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- 239000002718 pyrimidine nucleoside Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 108010014420 rab GTP-Binding Proteins Proteins 0.000 description 1
- 102000016949 rab GTP-Binding Proteins Human genes 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 108010005597 ran GTP Binding Protein Proteins 0.000 description 1
- 102000005912 ran GTP Binding Protein Human genes 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009305 regulation of actin filament polymerization Effects 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000007980 regulation of cell activation Effects 0.000 description 1
- 230000023252 regulation of cell development Effects 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000024122 regulation of cell motility Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 108091069025 single-strand RNA Proteins 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000019100 sperm motility Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000001324 spliceosome Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000031906 susceptibility to X-linked 2 autism Diseases 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 229940041007 third-generation cephalosporins Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 108091005990 tyrosine-phosphorylated proteins Proteins 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009447 viral pathogenesis Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Description
a)前記結合剤の存在下で試料をインキュベートするステップ、
b)場合により(optionally)、未結合(unbound)試料物質を洗浄除去するステップ、
c)細菌又はウイルス感染症に罹患している疑いがある対象からの試料中のHNLのレベルを測定するステップ、
d)ステップc)で測定されたHNLのレベルを、
(i)健常対象、
(i)細菌感染症に罹患していることが分かっている対象、及び
(iii)ウイルス感染症に罹患していることが分かっている対象
から場合により得た1つ又は複数の対照試料と比較するステップ、及び/又は
場合により、ステップc)で測定されたHNLのレベルを、健常対象、ウイルス感染症の対象及び/若しくは細菌感染症の対象を示す1つ若しくは複数の正規化された対照値と比較するステップ、
を含む。
a)上で定義した結合剤又は上で定義した診断用組成物若しくはキットを使用して、対象から得た試料中のHNLのポリペプチド濃度を測定するステップ、及び
b)ステップ(a)で決定されたHNLのポリペプチド濃度が所定の(pre-determined)第1の閾値(threshold value)より低い場合、前記対象について細菌感染症を除外するステップ、
を含む方法に関する。
a)上で定義した結合剤又は上で定義した診断用組成物若しくはキットを使用して、対象から得た試料中のHNLのポリペプチド濃度を測定するステップ、及び
b)ステップ(a)で決定されたHNLのポリペプチド濃度が所定の第1の閾値より高い場合、前記対象についてウイルス感染症を除外するステップ、
を含む方法を提供する。
a)上で定義した結合剤又は上で定義した診断用組成物若しくはキットを使用して、対象から得た試料中のHNLのポリペプチド濃度を測定するステップ、及び
b)ステップ(a)で決定されたHNLのポリペプチド濃度が所定の第1の閾値より高い場合、前記対象について細菌感染症を確定診断するステップ、
を含む方法に関する。
a)上で定義した結合剤又は上で定義した診断用組成物若しくはキットを使用して、対象から得た試料中のHNLのポリペプチド濃度を測定するステップ、及び
b)ステップ(a)で決定されたTRAILのポリペプチド濃度が所定の第1の閾値より低い場合、前記対象についてウイルス感染症を確定診断するステップ、
を含む方法を提供する。
a)対象から得た試料中のTRAILのポリペプチド濃度を測定するステップ、及び
b)ステップ(a)で決定されたTRAILのポリペプチド濃度が所定の第1の閾値より高い場合、前記対象について細菌感染症を除外するか又はウイルス感染症を確定診断するステップ、
をさらに含む。
a)対象から得た試料中のTRAILのポリペプチド濃度を測定するステップ、及び
b)ステップ(a)で決定されたTRAILのポリペプチド濃度が所定の第1の閾値より低い場合、前記対象について細菌感染症を確定診断するか又はウイルス感染症を除外するステップ、
をさらに含む。
a)上で定義した結合剤又は上で定義した診断用組成物若しくはキットを使用して、対象から得た試料中のHNL及びCRPの、場合によりTRAILのポリペプチド濃度を測定するステップ、
b)前記HNL及びCRP並びに場合によりTRAILの濃度(the concentrations)に所定の数学関数を適用してスコアを計算するステップ、
c)前記スコアを所定の基準値と比較するステップ、
を含む方法に関する。
a)上で定義した結合剤又は上で定義した診断用組成物若しくはキットを使用して、対象から得た試料中のHNL及びCRPの、場合によりTRAILのポリペプチド濃度を測定するステップ、
b)前記HNL及びCRP並びに場合によりTRAILの濃度(the concentrations)に所定の数学関数を適用してスコアを計算するステップ、
c)前記スコアを所定の基準値と比較するステップ
を含む方法を提供する。
a)上で定義した結合剤又は上で定義した診断用組成物若しくはキットを使用して、対象から得た試料中のHNLのポリペプチド濃度を測定するステップ、及び
b)ステップ(a)で決定されたHNLのポリペプチド濃度が所定の閾値より高い場合、前記対象が抗生物質処置を受けることを推奨する(recommending)ステップ、
c)ステップ(a)で決定されたHNLのポリペプチド濃度が所定の閾値より低い場合、患者が抗生物質処置を受けないことを推奨するステップ、又は
d)ステップ(a)で決定されたHNLのポリペプチド濃度が所定の閾値より低い場合、患者が抗ウイルス処置を受けることを推奨するステップ、
を含む方法を提供する。
ステップa)において対象から得た試料中のTRAILのポリペプチド濃度をさらに測定すること、及び
ステップb)においてステップ(a)で決定されたHNLのポリペプチド濃度が所定の閾値より高い場合、及びステップ(a)で決定されたTRAILの濃度が所定の閾値より低い場合、前記対象が抗生物質処置を受けることを推奨すること、
ステップc)においてステップ(a)で決定されたHNLのポリペプチド濃度が所定の閾値より低い場合、及びステップ(a)で決定されたTRAILのポリペプチド濃度が所定の閾値より高い場合、患者が抗生物質処置を受けないことを推奨すること、又は
ステップd)においてステップ(a)で決定されたHNLのポリペプチド濃度が所定の閾値より低い場合、及びステップ(a)で決定されたTRAILのポリペプチド濃度が所定の閾値より高い場合、患者が抗ウイルス処置を受けることを推奨すること、
をさらに含む。
a)上で定義した結合剤又は上で定義した診断用組成物若しくはキットを使用して、対象から得た試料中のHNLのポリペプチド濃度を測定するステップ、及び
b)ステップ(a)で決定されたHNLのポリペプチド濃度が所定の閾値より高い場合、前記試料を細菌の存在について検査することを推奨するステップ、又は
c)ステップ(a)で決定されたHNLのポリペプチド濃度が所定の閾値より低い場合、前記試料をウイルスの存在について検査することを推奨するステップ、
を含む方法に関する。
ステップa)において、対象から得た試料中のTRAILのポリペプチド濃度をさらに測定すること、及び
ステップb)において、ステップ(a)で決定されたHNLのポリペプチド濃度が所定の閾値より高い場合、及びステップ(a)で決定されたTRAILの濃度が所定の閾値より低い場合、前記試料を細菌の存在について検査することを推奨すること、
ステップc)において、ステップ(a)で決定されたHNLのポリペプチド濃度が所定の閾値より低い場合、及びステップ(a)で決定されたTRAILのポリペプチド濃度が所定の閾値より高い場合、前記試料をウイルスの存在について検査することを推奨すること
をさらに含む。
a)上で定義した結合剤又は上で定義した診断用組成物若しくはキットを使用して、対象から得た試料中のHNLのポリペプチド濃度と、TRAIL、IP10、IL1Ra又はMac−2BPからなる群から選択される1つ又は複数のポリペプチドのポリペプチド濃度とを測定するステップ、
b)測定された前記ポリペプチドの濃度(the concentrations)に所定の数学関数を適用してスコアを計算するステップ、
c)前記スコアを所定の基準値と比較するステップ、
を含む方法をさらに提供する。
a)上で定義した結合剤又は上で定義した診断用組成物若しくはキットを使用して、対象から得た試料中のHNLのポリペプチド濃度と、TRAIL、IL1RA、IP10、Mac−2BP、B2M、BCA−1、CHI3L1、エオタキシン、IL1a、MCP、CD62L、VEGFR2、CHP、CMPK2、CORO1C、EIF2AK2、ISG15、RPL22L1、RTN3、CD112、CD134、CD182、CD231、CD235A、CD335、CD337、CD45、CD49D、CD66A/C/D/E、CD73、CD84、EGFR、GPR162、HLA−A/B/C、ITGAM、NRG1、RAP1B、SELI、SPINT2、SSEA1、IgG非特異的結合分子、IL1、I−TAC及びTNFR1からなる群から選択される第1のポリペプチド決定基(determinant)のレベルとを測定するステップ、及び
b)(i)ポリペプチド決定基TRAIL、IL1RA、IP10、Mac−2BP、B2M、BCA−1、CHI3L1、エオタキシン、IL1a、MCP、CD62L、VEGFR2、CHP、CMPK2、CORO1C、EIF2AK2、ISG15、RPL22L1、RTN3、CD112、CD134、CD182、CD231、CD235A、CD335、CD337、CD45、CD49D、CD66A/C/D/E、CD73、CD84、EGFR、GPR162、HLA−A/B/C、ITGAM、NRG1、RAP1B、SELI、SPINT2、SSEA1、IgG非特異的結合分子、IL1、I−TAC及びTNFR1、
(ii)ポリペプチド決定基IFITM3、IFIT3、EIF4B、IFIT1、LOC26010、MBOAT2、MX1、OAS2、RSAD2、ADIPOR1、CD15、CD8A、IFITM1、及びIL7、
(iii)ポリペプチド決定基CRP、SAA、TREM−1、PCT、IL−8、TREM−1及びIL6、又は
(iv)非ポリペプチド決定基:年齢、絶対好中球数(absolute neutrophil count,ANC)、絶対リンパ球数(absolute lymphocyte count,ALC)、好中球(neutrophil)%(Neu(%))、リンパ球(lymphocyte)%(Lym(%))、単球(monocyte)%(Mono(%))、最大温度、発症からの期間、クレアチニン(Creatinine,Cr)、カリウム(K)、脈拍及び尿素、
からなる群から選択される第2の決定基のレベルを測定するステップ、
c)HNL、第1及び第2の決定基のレベルを基準値と比較することによって前記対象において感染症のタイプを同定するステップ、
を含み、前記第1及び/又は第2の決定基の測定がHNLの測定による(over)感染症のタイプの同定精度を増加させる、方法に関する。
a)上で定義した結合剤又は上で定義した診断用組成物若しくはキットを使用して、対象から得た試料中のHNLのポリペプチド濃度と、ABTB1、ADIPOR1、ARHGDIB、ARPC2、ATP6V0B、Clorf83、CD15、CES1、CORO1A、CSDA、EIF4B、EPSTI1、GAS7、HERC5、IFI6、KIAA0082、IFIT1、IFIT3、IFITM1、IFITM3、LIPT1、IL7R、ISG20、LOC26010、LY6E、LRDD、LTA4H、MAN1C1、MBOAT2、NPM1、OAS2、PARP12、PARP9、QARS、RAB13、RAB31、RAC2、RPL34、PDIA6、PTEN、RSAD2、SART3、SDCBP、SMAD9、SOCS3、TRIM22、SART3、UBE2N、XAF1、ZBP1、CRP及びMX1からなる群から選択される1つ又は複数のポリペプチド決定基のレベルを測定するステップと、
b)前記HNLのレベル及び前記1つ又は複数のポリペプチド決定基のレベルを基準値と比較することによって前記対象において感染症のタイプを同定するステップと、
を含む方法に関する。
配列番号26の配列を含む抗原に以前に曝露された動物から得た抗体産生細胞を培養するステップ、及び
抗体を提供するステップであって、得られた抗体を場合によりさらに修飾するステップを含む方法を提供する。好ましくは、前記抗体は、配列番号1〜6、7〜12、及び13〜18で示されるアミノ酸配列又はその機能的誘導体(functional derivative)を少なくとも1、2、3、4、5又は6つ含む結合領域を含む。
1)結合剤、例えば、配列番号8〜13、14〜19、及び20〜25で示されるようなCDRH1、CDRH2、CDRH3、CDRL1、CDRL2若しくはCDRL3、又はそれらの誘導体、のいずれか1、2、3、4、5又は6つを保持する抗体、
2)結合剤、例えば、CDRH1、CDRH2、CDRH3のすべてを保持し、場合によりそのようなCDRに1つ又は2つの変異を含む抗体であって、配列番号26に含まれるHNLエピトープとの特異的結合を示す抗体、
3)結合剤、例えば、CDRL1、CDRL2、CDRL3のすべてを保持し、場合によりそのようなCDRに1つ又は2つの変異を含む抗体、場合によりそのようなCDRに1つ又は2つの変異を含む抗体であって、配列番号26に含まれるHNLエピトープとの特異的結合を示す抗体、
4)結合剤、例えば抗体であって、例えばX線結晶解析によって判定して、本明細書に記載の抗体とHNLの同じエピトープに結合する抗体、或いは(or)(例えば、競合的ELISA若しくはBiacoreによって又は当技術分野において公知の他の方法によって評価して)約75%より多く、約80%より多く、又は約81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%若しくは95%より多くが(ヒト)HNLと結合するための、配列番号26に含まれるアミノ酸を含む立体構造エピトープに結合する抗体、
に関する。
(1)天然の核酸源中で同定され、通常は付随する少なくとも1つの混入核酸分子から分離された、又は
(2)バックグラウンド核酸からクローニングされた、増幅された、タグが付けられた、若しくは別様に区別された、
いずれかである核酸分子であり、したがって、目的の核酸の配列を決定する(determined)ことができる。単離された核酸分子は、該核酸分子(it)が自然界で見いだされる形態又は環境(setting)におけるもの以外である。しかし、単離された核酸分子は、抗体を通常に発現する細胞に含有される核酸分子を、例えば、該核酸分子が天然細胞のものとは異なる染色体位置にある場合には含む。
原型 例示的 好ましい置換
Ala(A) val;leu;ile; val
Arg(R) lys;gln;asn; lys
Asn(N) gln;his;asp,lys; gln;arg
Asp(D) glu;asn glu
Cys(C) ser;ala ser
Gln(Q) asn;glu asn
Glu(E) asp;gln asp
Gly(G) ala
His(H) asn;gin;lys;arg
Ile(I) leu;val;met;ala;leu;
phe;ノルロイシン leu
Leu(L) ノルロイシン;ile;val;met;
ala;phe ile
Lys(K) arg;gln;asn arg
Met(M) leu;phe;ile leu
Phe(F) leu;val;ile;ala;tyr
Pro(P) ala
Ser(S) thr
Thr(T) ser
Trp(W) tyr;phe tyr
Tyr(Y) trp;phe;thr;ser phe
Val(V) ile;leu;met;phe;ala;
ノルロイシン leu
(1)疎水性:ノルロイシン、met、ala、val、leu、ile、
(2)中性親水性:cys、ser、thr、
(3)酸性:asp、glu、
(4)塩基性:asn、gln、his、lys、arg、
(5)鎖配向に影響を及ぼす残基:gly、pro、及び
(6)芳香族:trp、tyr、phe。
− 前記結合剤の存在下で試料をインキュベートするステップ、
− 場合により、未結合試料物質を洗浄除去するステップ、
− 細菌感染症に罹患している疑いがあるか又は細菌感染症が確認されており、抗生物質治療を受けている対象からの試料中のHNLのレベルを測定するステップ、
− 場合により、ステップc)で測定されたHNLのレベルを、
(i)健常対象、
(ii)細菌感染症に罹患していることが分かっている対象
から場合により得た、1つ又は複数の対照試料と比較するステップ、
さらに場合により、ステップc)で測定されたHNLのレベルを、健常対象及び/若しくは細菌感染症の対象を示す1つ若しくは複数の正規化対照HNL値、並びに/又は処置前の患者からの試料におけるHNLのレベルと比較するステップ、
を含み、
細菌性疾患と診断された対象からの試料中のHNLのレベルを抗菌処置開始後の少なくも1つのさらなる時点で判定し、場合により、前記分析を反復するステップ、及びさらに場合により、抗菌治療前、その間及び/又はその後のHNLレベルを比較するステップを含む方法を提供する。
a)本明細書において上で定義した結合剤又は本明細書において上で定義した診断用組成物若しくはキットを使用して、対象から得た試料中のHNLのポリペプチド濃度を測定するステップ、及び
b)(i)ステップ(a)で決定されたHNLのポリペプチド濃度が所定の第1の閾値より低い場合、前記対象について細菌感染症を除外するステップ、又は
b)(ii)ステップ(a)で決定されたHNLのポリペプチド濃度が所定の第1の閾値より高い場合、前記対象についてウイルス感染症を除外するステップ、又は
b)(iii)ステップ(a)で決定されたHNLのポリペプチド濃度が所定の第1の閾値より高い場合、前記対象について細菌感染症を確定診断するステップ、又は
b)(iv)ステップ(a)で決定されたHNLのポリペプチド濃度が所定の第1の閾値より低い場合、前記対象についてウイルス感染症を確定診断するステップ。
b)ステップ(a)で決定されたHNLのポリペプチド濃度が所定の閾値より高い場合、前記対象が抗生物質処置を受けることを推奨するステップ、
c)ステップ(a)で決定されたHNLのポリペプチド濃度が所定の閾値より低い場合、患者が抗生物質処置を受けないことを推奨するステップ、又は
d)ステップ(a)で決定されたHNLのポリペプチド濃度が本明細書において上で定義した所定の閾値より低い場合、患者が抗ウイルス処置を受けることを推奨するステップ、
を含む方法に関する。
a)上で定義した結合剤又は上で定義した診断用組成物若しくはキットを使用して、対象から得た試料中のHNLのポリペプチド濃度を測定するステップ、及び
b)ステップ(a)で決定されたHNLのポリペプチド濃度が所定の閾値より高い場合、前記試料を細菌の存在について検査することを推奨するステップ、又は
c)ステップ(a)で決定されたHNLのポリペプチド濃度が所定の閾値より低い場合、前記試料をウイルスの存在について検査することを推奨するステップ
を含む方法に関する。
a)対象から得た試料中のTRAILのポリペプチド濃度を測定するステップ、及び
b)ステップ(a)で決定されたTRAILのポリペプチド濃度が所定の第1の閾値より高い場合、前記対象について細菌感染症を除外するか又はウイルス感染症を確定診断するステップ、
をさらに含む。
a)対象から得た試料中のTRAILのポリペプチド濃度を測定するステップ、及び
b)ステップ(a)で決定されたTRAILのポリペプチド濃度が所定の第1の閾値より低い場合、前記対象について細菌感染症を確定診断するか又はウイルス感染症を除外するステップ、
をさらに含む。
ステップa)において対象から得た試料中のTRAILのポリペプチド濃度をさらに測定すること、及び
ステップb)においてステップ(a)で決定されたHNLのポリペプチド濃度が所定の閾値より高い場合、及びステップ(a)で決定されたTRAILの濃度が所定の閾値より低い場合、前記対象が抗生物質処置を受けることを推奨すること、
ステップc)においてステップ(a)で決定されたHNLのポリペプチド濃度が所定の閾値より低い場合、及びステップ(a)で決定されたTRAILのポリペプチド濃度が所定の閾値より高い場合、患者が抗生物質処置を受けないことを推奨すること、又は
ステップd)においてステップ(a)で決定されたHNLのポリペプチド濃度が、本明細書において上で定義した所定の閾値より低い場合、及びステップ(a)で決定されたTRAILのポリペプチド濃度が所定の閾値より高い場合、患者が抗ウイルス処置を受けることを推奨すること、
をさらに含む。
ステップa)において対象から得た試料中のTRAILのポリペプチド濃度をさらに測定すること、及び
ステップb)においてステップ(a)で決定されたHNLのポリペプチド濃度が所定の閾値より高い場合、及びステップ(a)で決定されたTRAILの濃度が所定の閾値より低い場合、前記試料を細菌の存在について検査することを推奨すること、
ステップc)においてステップ(a)で決定されたHNLのポリペプチド濃度が所定の閾値より低い場合、及びステップ(a)で決定されたTRAILのポリペプチド濃度が所定の閾値より高い場合、前記試料をウイルスの存在について検査することを推奨すること、
をさらに含む。
a)上で定義した結合剤又は上で定義した診断用組成物若しくはキットを使用して、対象から得た試料中のHNLのポリペプチド濃度と、TRAIL、IP10、IL1Ra又はMac−2BPからなる群から選択される1つ又は複数のポリペプチドのポリペプチド濃度とを測定するステップ、
b)測定された前記ポリペプチドの濃度(the concentrations)に所定の数学関数を適用してスコアを計算するステップ、
c)前記スコアを所定の基準値と比較するステップ、
を含む方法も想定される。
a)上で定義した結合剤又は上で定義した診断用組成物若しくはキットを使用して、対象から得た試料中のHNL及びCRPの、場合によりTRAILのポリペプチド濃度を測定するステップ、
b)前記HNL及びCRP並びに場合によりTRAILの濃度(the concentrations)に所定の数学関数を適用してスコアを計算するステップ、
c)本明細書において上で定義したスコアを、本明細書において上で定義した所定の基準値と比較するステップ、
を含む方法に関する。
a)上で定義した結合剤又は上で定義した診断用組成物若しくはキットを使用して、対象から得た試料中のHNL及びCRPの、場合によりTRAILのポリペプチド濃度を測定するステップ、
b)前記HNL及びCRP並びに場合によりTRAIの濃度(the concentrations)に所定の数学関数を適用してスコアを計算するステップ、
c)本明細書において上で定義した、スコアを、本明細書において上で定義した所定の基準値と比較するステップ
を含む方法を提供する。
a)請求項1〜5のいずれか一項に記載の結合剤又は請求項6若しくは7に記載の診断用組成物若しくはキットを使用して、対象から得た試料中のHNLのポリペプチド濃度と、TRAIL、IL1RA、IP10、Mac−2BP、B2M、BCA−1、CHI3L1、エオタキシン、IL1a、MCP、CD62L、VEGFR2、CHP、CMPK2、CORO1C、EIF2AK2、ISG15、RPL22L1、RTN3、CD112、CD134、CD182、CD231、CD235A、CD335、CD337、CD45、CD49D、CD66A/C/D/E、CD73、CD84、EGFR、GPR162、HLA−A/B/C、ITGAM、NRG1、RAP1B、SELI、SPINT2、SSEA1、IgG非特異的結合分子、IL1、I−TAC及びTNFR1からなる群から選択される本明細書において上で定義した第1のポリペプチド決定基のレベルとを測定するステップ、及び
b)(i)本明細書において上で定義したポリペプチド決定基、TRAIL、IL1RA、IP10、Mac−2BP、B2M、BCA−1、CHI3L1、エオタキシン、IL1a、MCP、CD62L、VEGFR2、CHP、CMPK2、CORO1C、EIF2AK2、ISG15、RPL22L1、RTN3、CD112、CD134、CD182、CD231、CD235A、CD335、CD337、CD45、CD49D、CD66A/C/D/E、CD73、CD84、EGFR、GPR162、HLA−A/B/C、ITGAM、NRG1、RAP1B、SELI、SPINT2、SSEA1、IgG非特異的結合分子、IL1、I−TAC及びTNFR1、
(ii)本明細書において上で定義したポリペプチド決定基、IFITM3、IFIT3、EIF4B、IFIT1、LOC26010、MBOAT2、MX1、OAS2、RSAD2、ADIPOR1、CD15、CD8A、IFITM1、及びIL7、
(iii)本明細書において上で定義したポリペプチド決定基、CRP、SAA、TREM−1、PCT、IL−8、TREM−1及びIL6、又は
(iv)本明細書において上で定義した非ポリペプチド決定基:年齢、絶対好中球数(ANC)、絶対リンパ球数(ALC)、好中球%(Neu(%))、リンパ球%(Lym(%))、単球%(Mono(%))、最大温度、発症からの期間、クレアチニン(Cr)、カリウム(K)、脈拍及び尿素、
からなる群から選択される第2の決定基のレベルを測定するステップ、
c)HNL、第1及び第2の決定基のレベルを基準値と比較することによって前記対象において感染症のタイプを同定するステップ、
を含み、前記第1及び/又は第2の決定基の測定がHNLの測定による感染症のタイプの同定精度を増加させる、方法を提供する。
High−Mass MALDI質量分析によるエピトープマッピング
エピトープマッピングを開始する前に、High−Mass MALDI分析を各試料(抗体及び抗原)に関して行って、それらの完全性及び凝集レベルを検証した。完全性/凝集試験については、CovalXのHM3相互作用モジュールを装備したUltraflex III MALDI ToF質量分析計(Bruker)を使用して測定を行った。CovalXの相互作用モジュールは、ナノモル感度で2MDaまでの検出を最適化するように設計された特別な検出システムを含む。20μlの各タンパク質試料(抗HNLクローンMAB1;クローンMAB2及びクローンMAB3及びHNL)をピペッティングして、最終体積が10μである8つの希釈物(dilutions)を調製した。これらの希釈物中の抗体の濃度は、1.0mg/ml、0.5mg/ml、250μg/ml、125μg/ml、62.5μg/ml、31.25μg/ml、15.63μg/ml、7.82μg/mlであった。HNL抗原を希釈して、以下の濃度を得た:350μg/ml、175μg/ml、87.5μg/ml、43.75μg/ml、21.88μg/ml、10.94μg/ml、5.47μg/ml、及び2.74μg/ml。これら8つの試料希釈物を下記の予想濃度が得られるように調製した。
抗体抗HNL MAB1
対照実験では、1〜1/64のすべての希釈物についてMH+=146.935±0.098kDaを有する1つの主ピークが検出された。観測分子量(kDa)は、146.935±0.098 抗HNL MAB1である。
対照実験では、1〜1/64のすべての希釈物についてMH+=152.657±0.115kDaを有する1つの主ピークが検出された。観測分子量(kDa)は、152.657±0.115 抗HNL MAB2である。
対照実験では、1〜1/64のすべての希釈物についてMH+=147.717±0.133kDaを有する1つの主ピークが検出された。観測分子量(kDa)は、147.717±0.133 抗HNL MAB3である。
対照実験では、1〜1/32のすべての希釈物についてMH+=45.431±0.33kDaを有する1つの主ピークが検出された。観測分子量(kDa)は、45.431±0.33である。
High−Mass MALDI質量分析及び化学的架橋を使用して、抗体抗HNLと抗原HNLの多量体との非共有結合性凝集物は検出されなかった。
エピトープの性質(すなわち、直鎖状又は立体構造的)を決定するために、抗原タンパク質と抗体間の相互作用が、抗原のタンパク質分解によって産生される不定形ペプチドによって阻害されうるかどうかを評価した。
mAb/Agの混合物(抗HNL MAB1/HNL、抗HNL MAB2/HNL及び抗HNL MAB3/HNL)を調製した。得られた混合物1μlを、アセトニトリル/水(1:1 v/v)、TFA0.1%中の再結晶シナピン酸マトリックス(10mg/ml)で構成されているマトリックス(K200 MALDI Kit)1μlと混合した。混合後、1μlの各試料をMALDIプレート(SCOUT384)にスポッティングした。室温で晶出後、プレートをMALDI質量分析計に導入し、直ちに分析した。分析を3回ずつ繰り返した。
対照実験のために調製した混合物を(9μl残して)、CovalXのK200 MALDI MS分析キットを使用する架橋に付した。前記混合物の9μlは、1μlのK200 Stabilizer試薬(2mg/ml)と混合し、室温でインキュベートする。インキュベーション時間(180分)後、対照実験の場合と同様にMALDI分析のための試料を調製した。晶出後直ちにHigh−Mass MALDI分析によって試料を分析する。
エピトープの性質を決定するために、固定化ペプシンでのHNL抗原のタンパク質分解を行った。10μMの濃度を有する25μlの抗原を固定化ペプシン2.5μMと混合し、室温で30分間インキュベートした。インキュベーション時間の後、試料を遠心分離し、その上ずみをピペッティングした。タンパク質分解の完了を線形モード及びリフレクトロンモードでのHigh−Mass MALDI質量分析によって制御する。ペプシンタンパク質分解を最適化して、1000〜3500Da範囲の大量のペプチドを得た。タンパク質分解によって産生された5μlの抗原ペプチド(7.6μM)を5μlの抗HNL抗体(3.8μM)と混合し、37°で2時間インキュベートした。抗体と抗原ペプチドのインキュベーション後、5μlの混合物を5μlの無傷抗原(3.8μM)と混合する。
競合アッセイについての抗体/抗原相互作用分析は、上に記載したのと同じプロトコル(対照及び架橋実験)で行った。
MALDI Tof MS分析は、標準窒素レーザーを備えたCovalXのHM3相互作用モジュールを使用して、0〜2000kDaの様々な質量範囲に焦点を合わせて行った。分析には、以下のパラメータを適用した:質量分析計:リニア及びポジティブモード、イオン源1:20kV、イオン源2:17kV、レンズ:12kV、パルスイオン抽出:400ns、HM3:ゲイン電圧:3.14V、加速電圧:20kV。計器を較正するために、インスリン、BSA及びIgGのクラスターでの外部較正を適用した。各試料について3スポットを分析した(スポット当り300のレーザーショット)。提示スペクトルは、合計300のレーザーショットに対応する。MSデータは、CovalXのComplex Tracker分析ソフトウェアバージョン2.0を使用して分析した。
抗HNL MAB1/HNL
対照実験では、抗原及び抗体は、MH+=45.862kDa及びMH+=148.577kDaを有した。観測分子量(kDa)45.725 HNL;148.431 抗HNL MAB1。
対照実験では、抗原及び抗体は、それぞれ、MH+=45.755kDa及びMH+=148.531kDaを有した。観測分子量(kDa)は、45.755 HNL、及び148.531 抗HNL MAB2であった。
対照実験では、抗原及び抗体が、MH+=45.742kDa及びMH+=148.554kDaで検出された。観測分子量(kDa)は、それぞれ、45.742 HNL、及び148.554 抗HNL MAB3であった。
競合アッセイは、抗原のペプチドが抗原に対する抗体の結合を阻害しないことを示した。HNL上の抗HNLのエピトープは、直鎖状でない。
HNLを特徴づけるために、その試料をASP−N、トリプシン、キモトリプシン、エラスターゼ及びサーモリシンタンパク質分解に付し、その後、LC−LTQ Orbitrap MS/MS分析に付した。抗原の特徴づけのために、Ultimate 3000(Dionex)システムをLTQ Orbitrap XL質量分析計(Thermo)とインラインで使用してナノ−LCクロマトグラフィーを処理した。10μlの抗原(0.35mg/mL)を40μlの重炭酸アンモニウム(25mM、pH8.3)と混合した。混合後、2μlのDTT(500mM)をその溶液に添加する。その後、その混合物を1時間、55℃でインキュベートする。インキュベーション後、2μlのヨードアセトアミド(1M)を添加し、その後、1時間、室温で、暗所でインキュベートする。インキュベーション後、その溶液を、トリプシン、キモトリプシン、ASP−N、エラスターゼ又はサーモリシンでのタンパク質分解に使用した緩衝液120μlの添加によって、1/5希釈する:
HNL抗原上の抗HNL MAB1、抗HNL MAB2及び抗HNL MAB3のエピトープを高分解能で決定するために、これらの抗体/抗原複合体を重水素化された架橋剤とともにインキュベートし、多酵素切断に付す。架橋ペプチドの富化後、試料を高分解能質量分析(nLC−Orbitrap MS)によって分析し、生成されたデータを、XQuest及びStavroxソフトウェアを使用して分析する。
5μlの抗原試料(濃度3.8μM)を5μlの抗体試料(濃度1.9μM)と混合して、最終濃度0.95μM/1.9μMを有する抗体/抗原混合物を得た。この混合物を37℃で180分間インキュベートした。
架橋後、多酵素的タンパク質分解によって産生されたペプチドは、全抗原配列を95%カバーしている。
軽鎖可変領域:
DIVMTQTPATLSVTPGDSVSLSCRASQSIITDLHWYQQRSHESPRLLIKSASQSISGIPSRFSGSGSGTDFTLTINSVETEDFGMYFCQQSNSWPLTFGAGTKLELKRADAAPTVS
重鎖可変領域:
VQLQESGPDLVAPSQSLSITCTVSGFSLSSYGVHWVRQPPGKGLEWLIVMWSDGSTTSNSALKSRLSISKDNSKSQVFLKVNSLQSDDTAIYYCARHYGYFTMDYWGQGTSVTVSS
架橋後、多酵素的タンパク質分解によって産生されたペプチドは、全抗原配列を95%カバーしている。用意した抗HNL MAB2ハイブリドーマを使用してcDNAシークエンシングを行い、次の結果であった:
軽鎖可変領域:
DIVLTQSTSSLSVSLGDRVTINCRASQDISNYLNWYQEKPDGTVKLLIYFTSRLHSGVPSRFSGSGSGTDYSLTITNLEQEDIATYFCQQGNTLPWTFGGGTKLEIKRADAAPTV
重鎖可変領域:
EVQLEESGPGLVAPSQSLSITCTISGFSLTSYGIHWLRQPPGKDLEWLVVIWGDGSTTSNSALKSRLSISKDNSKSQVFFKMSGLQTDDTAIYYCARHRYSDYHAMDYWGPGTSVTVS
架橋後、多酵素的タンパク質分解によって産生されたペプチドは、全抗原配列を95%カバーしている。用意した抗HNL MAB3ハイブリドーマを使用してcDNAシークエンシングを行い、次の結果であった:
軽鎖可変領域:
DIVLTQTTSSLSVSLGDRVTINCRASQDISNYLNWYQEKPDGTVKLLIYFTSRLHSGVPSRFSGSGSGTDYSLTITNLEQEDIATYFCQQGNTLPWTFGGGTKLEIKRADAAPTV
重鎖可変領域:
EVKLQESGPGLVAPSQSLSITCTISGFSLTSYGIHWLRQPPGKDLEWLVVIWGDGSTTSNSALKSRLSISKDNSKSQVFFKMSGLQTDDTAIYYCARHRYSDYHAMDYWGPGTSVTVSS
HNLの高い判別力は、血清中の測定値で最も強調されるがEDTA血漿ではされず、これは、血清調製時にex vivoで試験管中の好中球がそれらのHNLを放出し続けることを示唆するように思われる。この放出活性は、ウイルスによってではなく細菌曝露によって誘導された好中球の活性化状態を表す。救急科において及び診療所において有用であるために、採血から任意のバイオマーカーの結果までの全アッセイ時間は、短い、すなわち15〜20分未満であるべきであり、これは、ポイントオブケア(POC)アッセイの開発の背景にある理念である。そのような要件は、HNLの血清測定に関しては相当困難である。上に示したように、HNLの血清測定は、好中球のかなり長い予備活性化を必要とするからである。確立した好中球活性化因子トリペプチドfMLPによる血液中の好中球の活性化がこの問題を回避する可能性を検査した。前記好中球活性化因子を使用して全血凝固中に起こる好中球活性化を模倣し、前記好中球活性化因子は長期インキュベーション後に血清中のHNLを測定する要求を置換する。
患者及び正常者の血液から精製した好中球を様々な濃度のfMLPに曝露し、15分間、37℃でインキュベートし、その後、遠心分離し、上清をHNLの存在についてアッセイした。fMLPの放出に最適な濃度は、5x10−8mol/Lであることが判明した。HNLの放出の反応速度を研究するために、精製細胞を様々な時間長にわたってインキュベートした。有意な放出が5分のインキュベーション後に見られ、インキュベーション延長によってさらに増加された(図2)。
ヘパリン化全血及びEDTA血漿を、急性感染症の症状がある患者600名及び感染していないように見える健常対象144名から採取した。調査したバイオマーカー(HNL、PCT、及び血中好中球上でのCD64発現)結果の知識を持たずに、感染患者を臨床的理由で細菌性の病因又はウイルス性の病因を有すると分類した。この分類は、CRPの白血球の濃度及び差異の知識を含んだ。患者240名を彼らの感染症について可能性の高い原因として細菌又はウイルスを有すると分類し、患者325名を彼らの感染症について可能性のある又は不確かな原因を有すると判断した。患者35名は、彼らの感染原因としてマイコプラズマを有した。彼らの感染症について可能性の高い原因を有する患者に関して、細菌培養及び/若しくはPCRなどの客観的検査、並びに/又は他の客観的検査によって感染症を確認した。CRP及び白血球数も診断に含めた。マイコプラズマ感染性に罹患している者がいない、この後者の患者群は、対象総計384名(健常:144名、細菌感染症:185名、ウイルス感染症:55名)を構成し、この報告書でバイオマーカーの診断性能を調査するために使用した群であった。
図4a及びbに、20分間、37℃で、EDTA血漿中でのfMLP活性化後の全血中のHNL濃度を示す。健常対象のfMLP活性化全血中のHNL濃度(幾何平均98μg/L、95%CI 90〜107μg/L)と比較して、細菌感染症を有する患者で測定された濃度(幾何平均337μg/L、95%CI 300〜379μg/L)(p<0.0001)及びウイルス感染症を有する患者で測定された濃度(幾何平均117μg/L、95%CI 101〜136μg/L)(p<0.05)は、有意に上昇された。
図6a〜dは、研究対象集団におけるバイオマーカー:CRP、血中好中球数、血中好中球上でのCD64発現、及びプロカルシトニン、の分布を示す。好中球数を除いて、他のすべてのバイオマーカーは、細菌感染症とウイルス感染症両方において健常対象と比較して有意に上昇した。バイオマーカーはすべて、ウイルス感染症に対して細菌感染症でのほうが有意に高かった(p<0.001)。平均濃度を表1に示す。
Claims (3)
- ヒト好中球リポカリン(HNL)のポリペプチドエピトープと特異的に結合するように構成された結合剤であって、
前記ポリペプチドエピトープが、当該結合剤が結合する配列番号1で定義されるHNLのアミノ酸141〜156を含み、
当該結合剤が、配列番号8〜13、14〜19、及び20〜25で示される少なくとも1、2、3、4、5、又は6つのエピトープ結合アミノ酸配列領域を含み、
結合親和性が、配列番号8〜13、14〜19、及び20〜25で示されるエピトープ結合アミノ酸配列領域で達成される結合特異性と比較して、少なくとも75%、80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、100%又はそれより高く、
当該結合剤が、軽鎖可変領域が配列番号2で示される配列を有し、重鎖可変領域が配列番号3で示される配列を有するモノクローナル抗体、軽鎖可変領域が配列番号4で示される配列を有し、重鎖可変領域が配列番号5で示される配列を有するモノクローナル抗体、軽鎖可変領域が配列番号6で示される配列を有し、重鎖可変領域が配列番号7で示される配列を有するモノクローナル抗体から選択され、且つ、配列番号8〜13、14〜19、及び20〜25で示されるようなCDRH1、CDRH2、CDRH3、CDRL1、CDRL2若しくはCDRL3のうちいずれか1、2、3、4、5又は6つを保持する、結合剤。 - 請求項1に記載の結合剤を含む、診断用組成物。
- 請求項1に記載の結合剤、場合により、使用説明書、緩衝液及び血液、血漿、血清、尿、脳脊髄液(CSF)、骨髄、唾液若しくは痰試料分析用デバイス、を含む、診断用キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14193886 | 2014-11-19 | ||
EP14193886.0 | 2014-11-19 | ||
PCT/EP2015/077045 WO2016079219A1 (en) | 2014-11-19 | 2015-11-19 | Diagnostic method employing hnl |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017536361A JP2017536361A (ja) | 2017-12-07 |
JP6788586B2 true JP6788586B2 (ja) | 2020-11-25 |
Family
ID=51945737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017526552A Active JP6788586B2 (ja) | 2014-11-19 | 2015-11-19 | Hnlを用いる診断方法 |
Country Status (7)
Country | Link |
---|---|
US (2) | US11270782B2 (ja) |
EP (1) | EP3221340A1 (ja) |
JP (1) | JP6788586B2 (ja) |
CN (1) | CN107001455B (ja) |
BR (1) | BR112017010268B1 (ja) |
RU (1) | RU2758608C2 (ja) |
WO (1) | WO2016079219A1 (ja) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013217935B2 (en) | 2012-02-09 | 2018-05-17 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections and methods of use thereof |
RU2730836C2 (ru) | 2014-08-14 | 2020-08-26 | Мемед Диагностикс Лтд. | Вычислительный анализ биологических данных с применением многообразия и гиперплоскости |
US20170234873A1 (en) | 2014-10-14 | 2017-08-17 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof |
CN115482925A (zh) * | 2016-01-28 | 2022-12-16 | 贝克曼考尔特公司 | 感染检测和区分系统及方法 |
EP3423590A4 (en) | 2016-03-03 | 2020-02-26 | Memed Diagnostics Ltd. | DETERMINANTS OF RNA TO DIFFERENTIATE BACTERIAL VIRAL INFECTIONS |
US11519923B2 (en) | 2016-06-21 | 2022-12-06 | Siemens Healthineers Nederland B.V. | Analyte detection system and method |
US11125744B2 (en) | 2016-06-30 | 2021-09-21 | Siemens Healthineers Nederland B.V. | Device, system and method for detecting an analyte in a body fluid sample containing a plurality of cells |
EP4141448A1 (en) | 2016-07-10 | 2023-03-01 | MeMed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
EP4184167A1 (en) * | 2016-07-10 | 2023-05-24 | MeMed Diagnostics Ltd. | Early diagnosis of infections |
EP3519833A4 (en) | 2016-09-29 | 2020-06-03 | MeMed Diagnostics Ltd. | PROGNOSTIC AND TREATMENT METHODS |
WO2018060999A1 (en) | 2016-09-29 | 2018-04-05 | Memed Diagnostics Ltd. | Methods of risk assessment and disease classification |
US10902951B2 (en) | 2016-10-17 | 2021-01-26 | Reliant Immune Diagnostics, Inc. | System and method for machine learning application for providing medical test results using visual indicia |
US11651866B2 (en) | 2016-10-17 | 2023-05-16 | Reliant Immune Diagnostics, Inc. | System and method for real-time insurance quote in response to a self-diagnostic test |
US11107585B2 (en) | 2016-10-17 | 2021-08-31 | Reliant Immune Diagnostics, Inc | System and method for a digital consumer medical wallet and storehouse |
US11802868B2 (en) * | 2016-10-17 | 2023-10-31 | Reliant Immune Diagnostics, Inc. | System and method for variable function mobile application for providing medical test results |
US11693002B2 (en) | 2016-10-17 | 2023-07-04 | Reliant Immune Diagnostics, Inc. | System and method for variable function mobile application for providing medical test results using visual indicia to determine medical test function type |
US11579145B2 (en) * | 2016-10-17 | 2023-02-14 | Reliant Immune Diagnostics, Inc. | System and method for image analysis of medical test results |
US9857372B1 (en) | 2016-10-17 | 2018-01-02 | Reliant Immune Diagnostics, LLC | Arbovirus indicative birth defect risk test |
CA3049582A1 (en) * | 2017-01-08 | 2018-07-12 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Systems and methods for using supervised learning to predict subject-specific bacteremia outcomes |
CN107843732B (zh) * | 2017-09-29 | 2019-09-06 | 北京市心肺血管疾病研究所 | 检测肺栓塞的血清标志物及其应用 |
CN108492877B (zh) * | 2018-03-26 | 2021-04-27 | 西安电子科技大学 | 一种基于ds证据理论的心血管病辅助预测方法 |
CN108486246B (zh) * | 2018-06-06 | 2020-06-09 | 青岛泱深生物医药有限公司 | 子痫前期的诊治标志物 |
WO2020035028A1 (zh) * | 2018-08-16 | 2020-02-20 | 苏州芬瑞医疗诊断科技有限公司 | 感染的检测 |
WO2021011356A1 (en) | 2019-07-12 | 2021-01-21 | Beckman Coulter, Inc. | Systems and methods for evaluating immune response to infection |
WO2021117044A1 (en) * | 2019-12-11 | 2021-06-17 | Ichilov Tech Ltd. | Non-invasive assay for differentiating between bacterial and viral infections |
JPWO2022004730A1 (ja) * | 2020-06-30 | 2022-01-06 | ||
US11175293B1 (en) | 2021-01-04 | 2021-11-16 | University Of Utah Research Foundation | Rapid assay for detection of SARS-CoV-2 antibodies |
WO2022155608A2 (en) * | 2021-01-15 | 2022-07-21 | The General Hospital Corporation | Cd64 chimeric receptor and uses thereof |
CN114573678B (zh) * | 2022-03-11 | 2022-12-27 | 中山大学 | 一种Rheb蛋白激活剂及其应用 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US535968A (en) | 1895-03-19 | Pessary | ||
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4452901A (en) | 1980-03-20 | 1984-06-05 | Ciba-Geigy Corporation | Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
JP3068180B2 (ja) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | 異種抗体の生成 |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
EP0656941B1 (en) | 1992-03-24 | 2005-06-01 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2177367A1 (en) | 1993-12-03 | 1995-06-08 | Andrew David Griffiths | Recombinant binding proteins and peptides |
SE9401351D0 (sv) | 1994-04-21 | 1994-04-21 | Venge | A method for diagnosis |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
KR20080059467A (ko) | 1996-12-03 | 2008-06-27 | 아브게닉스, 인크. | 복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체 |
US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US7560534B2 (en) | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
JP2003275949A (ja) | 2002-01-15 | 2003-09-30 | Seiko Epson Corp | 研磨方法及び研磨装置 |
JP2005530490A (ja) | 2002-03-29 | 2005-10-13 | シェーリング コーポレイション | インターロイキン−5に対するヒトモノクローナル抗体および方法およびこれを含む組成物 |
US7056702B2 (en) * | 2002-12-16 | 2006-06-06 | Kimberly Clark Co | Detecting lipocalin |
US8040430B2 (en) | 2003-07-18 | 2011-10-18 | Nikon Corporation | Battery capacity display device and camera |
ES2703434T3 (es) * | 2004-12-20 | 2019-03-08 | Antibodyshop As | Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales |
US8614101B2 (en) | 2008-05-20 | 2013-12-24 | Rapid Pathogen Screening, Inc. | In situ lysis of cells in lateral flow immunoassays |
AU2007217861A1 (en) * | 2006-02-17 | 2007-08-30 | Children's Medical Center Corporation | Free NGAL as a biomarker for cancer |
US7645616B2 (en) | 2006-10-20 | 2010-01-12 | The University Of Hong Kong | Use of lipocalin-2 as a diagnostic marker and therapeutic target |
CN101558305A (zh) | 2006-12-12 | 2009-10-14 | 皇家飞利浦电子股份有限公司 | 用于检测标记颗粒的微电子传感器装置 |
ATE471516T1 (de) | 2007-02-23 | 2010-07-15 | Koninkl Philips Electronics Nv | Sensorvorrichtung und verfahren zum detektieren magnetischer partikel |
JP2011501673A (ja) * | 2007-10-19 | 2011-01-13 | アボット・ラボラトリーズ | グリコシル化された哺乳動物ngal及びその使用 |
RU2494375C2 (ru) | 2008-09-25 | 2013-09-27 | Конинклейке Филипс Электроникс Н.В. | Система и способ детектирования |
CN102458459A (zh) * | 2009-05-01 | 2012-05-16 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
US9772272B2 (en) | 2009-09-28 | 2017-09-26 | Koninklijke Philips N.V. | Substance determining apparatus |
WO2011053832A1 (en) | 2009-10-29 | 2011-05-05 | The Trustees Of Columbia University In The City Of New York | Use of urinary ngal to diagnose sepsis in very low birth weight infants |
CN102221608A (zh) * | 2011-04-06 | 2011-10-19 | 浙江大学医学院附属第一医院 | 一种抗体组合物及其应用 |
AU2013217935B2 (en) * | 2012-02-09 | 2018-05-17 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections and methods of use thereof |
WO2013132347A2 (en) | 2012-03-06 | 2013-09-12 | Calpro As | Improved elisa immunoassay for calprotectin |
GB201211982D0 (en) * | 2012-07-05 | 2012-08-22 | Isis Innovation | Biomarker |
EP2952948B1 (en) | 2014-06-06 | 2023-05-17 | Airbus Defence and Space GmbH | Thermal heating device using light for binder activation and its integration in preforming device |
-
2015
- 2015-11-19 WO PCT/EP2015/077045 patent/WO2016079219A1/en active Application Filing
- 2015-11-19 US US15/528,141 patent/US11270782B2/en active Active
- 2015-11-19 BR BR112017010268-4A patent/BR112017010268B1/pt active IP Right Grant
- 2015-11-19 EP EP15798395.8A patent/EP3221340A1/en active Pending
- 2015-11-19 CN CN201580063084.6A patent/CN107001455B/zh active Active
- 2015-11-19 RU RU2017121108A patent/RU2758608C2/ru active
- 2015-11-19 JP JP2017526552A patent/JP6788586B2/ja active Active
-
2022
- 2022-02-03 US US17/591,631 patent/US20220165372A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR112017010268A2 (pt) | 2018-02-06 |
BR112017010268B1 (pt) | 2024-01-16 |
US20220165372A1 (en) | 2022-05-26 |
US20170356921A1 (en) | 2017-12-14 |
WO2016079219A1 (en) | 2016-05-26 |
RU2758608C2 (ru) | 2021-11-01 |
RU2017121108A3 (ja) | 2019-06-24 |
US11270782B2 (en) | 2022-03-08 |
JP2017536361A (ja) | 2017-12-07 |
EP3221340A1 (en) | 2017-09-27 |
RU2017121108A (ru) | 2018-12-19 |
CN107001455B (zh) | 2022-03-01 |
CN107001455A (zh) | 2017-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6788586B2 (ja) | Hnlを用いる診断方法 | |
JP7153775B2 (ja) | Il23経路バイオマーカーを使用するil23アンタゴニストに対する臨床応答の予測 | |
AU2018202302C1 (en) | Signatures And Determinants For Diagnosing Infections And Methods Of Use Thereof | |
US20220144935A1 (en) | Ccl20 as a predictor of clinical response to il23-antagonists | |
KR20140066991A (ko) | 감도가 증진된 세포 매개 면역 반응 검정법 | |
KR20200037258A (ko) | 생물학적 약물로 치료받은 피험자에서 중화 항체 수준 평가용 분석법 및 맞춤 의료에서 이의 사용 | |
US20190094223A1 (en) | Infiltrating immune cell proportions predict anti-tnf response in colon biopsies | |
US20130216557A1 (en) | Ltbr blockade: methods for optimizing therapeutic responsiveness of patients | |
JP2022505422A (ja) | 疾患活動性を特徴付ける全身性エリテマトーデス(sle)疾患活動性免疫指標のバイオマーカー | |
EP4019643A1 (en) | Biomarkers for assessing subjects with multiple sclerosis | |
André et al. | Low quantity and quality of anti-spike humoral response is linked to CD4 T-cell apoptosis in COVID-19 patients | |
CN114502960A (zh) | 预测系统性红斑狼疮活动事件的可溶性介质 | |
WO2021231436A1 (en) | Therapeutic methods for treating covid-19 infections | |
Amjadi | Antibody responses after SARS-CoV-2 infection | |
KR20240045370A (ko) | 펩티드 조성물 및 그의 용도 | |
Notarnicola | Studies on pathogenesis, clinical features and comorbidities of Idiopathic Inflammatory Myopathies | |
CN117178190A (zh) | 用于检测sars-cov-2的测定 | |
Class et al. | Patent application title: SIGNATURES AND DETERMINANTS FOR DIAGNOSING INFECTIONS AND METHODS OF USE THEREOF Inventors: Kfir Oved (Moshav Megadim, IL) Eran Eden (Haifa, IL) Ilan Ifergan (Haifa, IL) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181116 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191029 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200109 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200331 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200521 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20200521 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20200529 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20200602 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200707 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200923 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201006 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201030 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6788586 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |